**Summary of HUTCHMED (China) Limiteds 2025 Full Year Results and Business Updates**
HUTCHMED (China) Limited reported robust financial and operational performance for the year ended December 31, 2025, highlighting significant advancements in its pipeline, commercial expansion, and financial health.
**Financial Highlights**
**Net Income** $456.9 million, driven by profitable core operations and a $415.8 million divestment gain from the partial sale of SHPL.
**Revenue** $548.5 million, down 13% from 2024 due to lower oncology product revenue in China and reduced milestone payments.
**In-Market Sales** $524.7 million, up 5%, with FRUZAQLA® (fruquintinib ex-China) sales by Takeda rising 26% to $366.2 million, offset by declines in ELUNATE® and ORPATHYS® in China.
**Cash Position** $1.4 billion, bolstered by divestment proceeds and operational cash flows.
**Commercial Progress**
**FRUZAQLA®** Strong global growth, with approvals in 38 countries and launches in Europe, Asia, and the Americas.
**ELUNATE®** Sales stabilized in H2 2025 after initial headwinds, supported by refocused commercial strategies.
**ORPATHYS®** Triggered an $11.0 million milestone payment from AstraZeneca for China approval in lung cancer.
**Pipeline Advances**
**ATTC Platform** Initiated first clinical trial for HMPL-A251 in December 2025, with HMPL-A580 and HMPL-A830 trials progressing.
**Late-Stage Programs** Positive Phase III results for FRUSICA-2 (RCC), ESLIM-02 (wAIHA), and SULANDA®-based combinations, leading to regulatory filings and approvals.
**Regulatory Milestones** Savolitinib approvals in China and Switzerland, fanregratinib NDA acceptance, and tazemetostat conditional approval.
**Strategic Initiatives**
**Partnerships** Exploring collaborations with multinational pharmaceutical companies for ATTC candidates.
**Sustainability** Achieved ESG recognition with A ratings from MSCI and Wind, and inclusion in the S&P Global Sustainability Yearbook 2025.
**Leadership and Outlook**
**Management** Restructured commercial team to drive growth, with significant improvements in H2 2025.
**Guidance** 2026 oncology/immunology revenue projected at $330–$450 million, supported by FRUZAQLA® expansion and new partnerships.
HUTCHMED remains focused on innovation, global expansion, and financial sustainability, positioning itself as a leader in novel cancer therapies.
Below is the HTML table code comparing the financials and debt year on year based on the provided text:
### Key Notes:
1. **Revenue**: Decreased by 13% year-on-year, primarily due to lower oncology/immunology revenue.
2. **Net Income**: Significantly increased due to a $415.8 million divestment gain from SHPL.
3. **Cash Position**: Improved by 63% due to the divestment proceeds.
4. **R&D Expenses**: Reduced by 30% as higher-cost late-stage trials were completed.
5. **Debt (Bank Borrowings)**: Increased slightly from $82.8 million to $93.2 million. This table provides a concise comparison of key financial metrics between 2025 and 2024.
